The Johns Hopkins-led and NIH funded OUtMATCH study led to the development of Xolair, a groundbreaking drug that reduces the ...

The standard regimen of omalizumab is often modified in patients with chronic spontaneous urticaria, with several factors predicting dose adjustments.

Clear Street initiated coverage of Rapt Therapeutics with a Buy rating and set a $3 price target, as the research firm has ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the respiratory community has seen a continuous growth in the number of biologics ...

Findings showed equivalent efficacy in change from baseline in weekly itch severity score between omalizumab-igec 300mg and Xolair 300mg. The Food and Drug Administration (FDA) has approved ...

Last year, the US Food and Drug Administration (FDA) approved omalizumab— an injectable medication already used for allergic asthma, chronic hives, and nasal polyps — for food allergies in ...

JERSEY CITY, N.J., March 10, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO ® (omalizumab-igec) as the first and only biosimilar designated ...

In the intent-to-treat analysis including 117 children with allergy to peanut and two other foods, 36% of those who received an extended course of omalizumab tolerated a cumulative total dose of ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small ...

Thirty-six percent of patients treated with omalizumab were able to tolerate 2000mg of peanut protein and 2 other food allergens without experiencing an allergic reaction compared with 19% of OIT ...

New research, led by Johns Hopkins Children’s Center investigators and sponsored by the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID), finds that ...